The growth of private firms is one of the key topics during China's ongoing "two sessions", which offers a glimpse into the country's policy priorities.

In the bustling labs of Shanghai's Zhangjiang Hi-tech Park, a quiet revolution is underway. Immunofoco, a pioneering biotech company, is leading the charge in developing CAR-T cell therapies for solid tumors — a breakthrough that could transform cancer treatment worldwide.